Oruka Therapeutics Inc (ORKA) Actualités

Form EFFECT - Notice of Effectiveness

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and...

Form POS AM - Post-Effective amendments for registration statement

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Oruka Therapeutics to Present at Multiple March Investor Conferences

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to...